H.C. Wainwright maintained a Buy rating on Lexicon Pharmaceuticals, Inc. (LXRX) on March 05, 2026 and raised the price target to $6. This single-item update is the latest LXRX analyst rating movement and gives investors a clearer short-term reference for valuation.
This article is available in full on our main platform. Get access to complete analysis, stock insights, and more.
Read Full Article →
Intraday GU5.SI stock: China Kunda trades S$0.018 on SES with volume 4.686M and Meyka AI monthly forecast S$0.02
Live analysis of 8729.T stock at JPY 161.70 on 16 Feb 2026 with volume, valuation, technicals and a Meyka AI forecast
BNB USD trades at $907.16 with technical analysis showing RSI at 52 and quarterly forecast of $1,032. Market data and price targets explained.
Hong Kong data breach law set for revival: PDPO amendments may mandate breach reporting and add administrative fines. What US investors and companies should do now.
VTXB stock surges 9900% to $0.0001 on PNK on 14 Feb 2026; quick analysis, Meyka AI grade and forecast for VTXB stock
MIRL.CN stock trades at C$0.015 on CNQ with an oversold bounce set-up and a short-term C$0.03 target